IMMUNOTERAPIA NEOADIUVANTE CON INTERLEUCHINA-2 IN PAZIENTI AFFETTI DA CARCINOMA VESCICALE DI BASSO STADIO. ASPETTI CLINICI ED IMMUNOLOGICI

Translated title of the contribution: Neoadjuvant immunotherapy with interleukin-2 in patients with early-stage bladder carcinoma. Clinical and immunological aspects

L. Miano, A. Tubaro, C. Vicentini, P. Galassi, P. C. Bossola, F. Scapellato, F. Velotti, A. Pettinato, S. Morrone, T. Napolitano, A. Santoni, A. Stoppacciaro, L. Ruco, F. Franks, P. Palmer, C. Pourreau

Research output: Contribution to journalArticle

Abstract

Between June 1988 and July 1989, 10 patients affected by transitional cell carcinoma of the bladder (Ta-T1, N0, M0; G1-2) were enrolled in this clinical trial. A dose escalating scheme from 18 x 103 to 18 x 106 IU/m2/day was used in subgroups of 3 patients each. Two five-day cycles of rIL-2, with a 48-hour interruption in between, were administered. Continuous intra-arterial infusion was performed through a 5 Fr angiographic catheter in the hypogastric artery. Transurethral resection of the bladder tumor was performed 4 days after the end of the 2nd cycle. Two complete and two partial responses were observed out of 10 treated patients. In 6 cases, no modification of the tumor was observed. Immunological monitoring of peripheral blood lymphocytes demonstrated activation of T lymphocyte subpopulations and increase of NK, LAK and ADCC cytotoxicity in some patients.

Original languageItalian
Pages (from-to)63-68
Number of pages6
JournalActa Urologica Italica
Volume4
Issue number6 SUPPL. 1
Publication statusPublished - 1990

Fingerprint

Immunotherapy
Interleukin-2
Urinary Bladder
Carcinoma
Antibody-Dependent Cell Cytotoxicity
Immunologic Monitoring
Intra Arterial Infusions
Transitional Cell Carcinoma
Lymphocyte Subsets
Lymphocyte Activation
Urinary Bladder Neoplasms
Catheters
Arteries
Clinical Trials
T-Lymphocytes
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Miano, L., Tubaro, A., Vicentini, C., Galassi, P., Bossola, P. C., Scapellato, F., ... Pourreau, C. (1990). IMMUNOTERAPIA NEOADIUVANTE CON INTERLEUCHINA-2 IN PAZIENTI AFFETTI DA CARCINOMA VESCICALE DI BASSO STADIO. ASPETTI CLINICI ED IMMUNOLOGICI. Acta Urologica Italica, 4(6 SUPPL. 1), 63-68.

IMMUNOTERAPIA NEOADIUVANTE CON INTERLEUCHINA-2 IN PAZIENTI AFFETTI DA CARCINOMA VESCICALE DI BASSO STADIO. ASPETTI CLINICI ED IMMUNOLOGICI. / Miano, L.; Tubaro, A.; Vicentini, C.; Galassi, P.; Bossola, P. C.; Scapellato, F.; Velotti, F.; Pettinato, A.; Morrone, S.; Napolitano, T.; Santoni, A.; Stoppacciaro, A.; Ruco, L.; Franks, F.; Palmer, P.; Pourreau, C.

In: Acta Urologica Italica, Vol. 4, No. 6 SUPPL. 1, 1990, p. 63-68.

Research output: Contribution to journalArticle

Miano, L, Tubaro, A, Vicentini, C, Galassi, P, Bossola, PC, Scapellato, F, Velotti, F, Pettinato, A, Morrone, S, Napolitano, T, Santoni, A, Stoppacciaro, A, Ruco, L, Franks, F, Palmer, P & Pourreau, C 1990, 'IMMUNOTERAPIA NEOADIUVANTE CON INTERLEUCHINA-2 IN PAZIENTI AFFETTI DA CARCINOMA VESCICALE DI BASSO STADIO. ASPETTI CLINICI ED IMMUNOLOGICI', Acta Urologica Italica, vol. 4, no. 6 SUPPL. 1, pp. 63-68.
Miano, L. ; Tubaro, A. ; Vicentini, C. ; Galassi, P. ; Bossola, P. C. ; Scapellato, F. ; Velotti, F. ; Pettinato, A. ; Morrone, S. ; Napolitano, T. ; Santoni, A. ; Stoppacciaro, A. ; Ruco, L. ; Franks, F. ; Palmer, P. ; Pourreau, C. / IMMUNOTERAPIA NEOADIUVANTE CON INTERLEUCHINA-2 IN PAZIENTI AFFETTI DA CARCINOMA VESCICALE DI BASSO STADIO. ASPETTI CLINICI ED IMMUNOLOGICI. In: Acta Urologica Italica. 1990 ; Vol. 4, No. 6 SUPPL. 1. pp. 63-68.
@article{13f76e5c15644529a6f32e85f8f45d6d,
title = "IMMUNOTERAPIA NEOADIUVANTE CON INTERLEUCHINA-2 IN PAZIENTI AFFETTI DA CARCINOMA VESCICALE DI BASSO STADIO. ASPETTI CLINICI ED IMMUNOLOGICI",
abstract = "Between June 1988 and July 1989, 10 patients affected by transitional cell carcinoma of the bladder (Ta-T1, N0, M0; G1-2) were enrolled in this clinical trial. A dose escalating scheme from 18 x 103 to 18 x 106 IU/m2/day was used in subgroups of 3 patients each. Two five-day cycles of rIL-2, with a 48-hour interruption in between, were administered. Continuous intra-arterial infusion was performed through a 5 Fr angiographic catheter in the hypogastric artery. Transurethral resection of the bladder tumor was performed 4 days after the end of the 2nd cycle. Two complete and two partial responses were observed out of 10 treated patients. In 6 cases, no modification of the tumor was observed. Immunological monitoring of peripheral blood lymphocytes demonstrated activation of T lymphocyte subpopulations and increase of NK, LAK and ADCC cytotoxicity in some patients.",
author = "L. Miano and A. Tubaro and C. Vicentini and P. Galassi and Bossola, {P. C.} and F. Scapellato and F. Velotti and A. Pettinato and S. Morrone and T. Napolitano and A. Santoni and A. Stoppacciaro and L. Ruco and F. Franks and P. Palmer and C. Pourreau",
year = "1990",
language = "Italian",
volume = "4",
pages = "63--68",
journal = "Acta Urologica Italica",
issn = "0394-2511",
publisher = "S. Karger AG",
number = "6 SUPPL. 1",

}

TY - JOUR

T1 - IMMUNOTERAPIA NEOADIUVANTE CON INTERLEUCHINA-2 IN PAZIENTI AFFETTI DA CARCINOMA VESCICALE DI BASSO STADIO. ASPETTI CLINICI ED IMMUNOLOGICI

AU - Miano, L.

AU - Tubaro, A.

AU - Vicentini, C.

AU - Galassi, P.

AU - Bossola, P. C.

AU - Scapellato, F.

AU - Velotti, F.

AU - Pettinato, A.

AU - Morrone, S.

AU - Napolitano, T.

AU - Santoni, A.

AU - Stoppacciaro, A.

AU - Ruco, L.

AU - Franks, F.

AU - Palmer, P.

AU - Pourreau, C.

PY - 1990

Y1 - 1990

N2 - Between June 1988 and July 1989, 10 patients affected by transitional cell carcinoma of the bladder (Ta-T1, N0, M0; G1-2) were enrolled in this clinical trial. A dose escalating scheme from 18 x 103 to 18 x 106 IU/m2/day was used in subgroups of 3 patients each. Two five-day cycles of rIL-2, with a 48-hour interruption in between, were administered. Continuous intra-arterial infusion was performed through a 5 Fr angiographic catheter in the hypogastric artery. Transurethral resection of the bladder tumor was performed 4 days after the end of the 2nd cycle. Two complete and two partial responses were observed out of 10 treated patients. In 6 cases, no modification of the tumor was observed. Immunological monitoring of peripheral blood lymphocytes demonstrated activation of T lymphocyte subpopulations and increase of NK, LAK and ADCC cytotoxicity in some patients.

AB - Between June 1988 and July 1989, 10 patients affected by transitional cell carcinoma of the bladder (Ta-T1, N0, M0; G1-2) were enrolled in this clinical trial. A dose escalating scheme from 18 x 103 to 18 x 106 IU/m2/day was used in subgroups of 3 patients each. Two five-day cycles of rIL-2, with a 48-hour interruption in between, were administered. Continuous intra-arterial infusion was performed through a 5 Fr angiographic catheter in the hypogastric artery. Transurethral resection of the bladder tumor was performed 4 days after the end of the 2nd cycle. Two complete and two partial responses were observed out of 10 treated patients. In 6 cases, no modification of the tumor was observed. Immunological monitoring of peripheral blood lymphocytes demonstrated activation of T lymphocyte subpopulations and increase of NK, LAK and ADCC cytotoxicity in some patients.

UR - http://www.scopus.com/inward/record.url?scp=0025535733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025535733&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0025535733

VL - 4

SP - 63

EP - 68

JO - Acta Urologica Italica

JF - Acta Urologica Italica

SN - 0394-2511

IS - 6 SUPPL. 1

ER -